• Structure Therapeutics posted a Q1 net loss of $76 million, widening from $46.8 million a year earlier.
• R&D expense climbed to $66.5 million from $42.9 million, while G&A costs rose to $22.9 million from $13.4 million.
• Cash, cash equivalents and short-term investments totaled $1.5 billion as of March 31, 2026, with runway expected through end-2028.
• Reported Phase 2 ACCESS II results for oral GLP-1 agonist aleniglipron showing placebo-adjusted mean weight loss of 16.3% at 180 mg and 16.0% at 240 mg at 44 weeks.
• Phase 3 initiation for aleniglipron remains on track for Q3 2026 following positive end-of-Phase 2 FDA feedback, with additional ACCESS OLE data due in Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.